Healthcare Industry News: XmAb
News Release - February 1, 2007
Xencor Appoints Jade R. Brown as Vice President of Business DevelopmentMONROVIA, Calif.--(HSMN NewsFeed)--Xencor, a company developing protein and antibody therapeutics, announced today the appointment of Jade R. Brown to Vice President of Business Development. He brings to the position more than 16 years of experience in the pharmaceutical industry as a business development executive leading high profile transactions both nationally and internationally.
"Jade's breadth of knowledge and diversity of transactional experience will be a great asset to the company as we move into the clinic this year, and as we forge additional partnerships that extend the value of our technology platform," said Bassil Dahiyat, Ph.D., President and CEO of Xencor.
Mr. Brown was most recently Chief Business Officer at Cell Therapeutics, Inc. where he led the company's business development, European affiliate, manufacturing, operations and marketing. Prior to that, he served as Vice President of Business Development and Marketing at Nastech Pharmaceuticals. For more than 12 years, he served at Eli Lilly and Company, where he held various business development and commercialization leadership positions including Brand Director in the Women's Health Division. He received his Masters from Harvard University Graduate School of Business and a Bachelor of Science in Business from Indiana University.
Xencor, Inc. engineers superior biotherapeutics using its proprietary Protein Design Automation® technology platform and is a leader in the field of antibody Fc engineering to significantly improve antibody potency. The company is internally advancing both XPro(TM) protein therapeutic candidates and XmAb(TM) antibody drug candidates optimized for activity against biologically validated targets. Xencor's product development is led by a protein therapeutic drug candidate, XPro(TM)1595, for the treatment of inflammatory disorders and an antibody candidate, XmAb(TM)2513, for the treatment of Hodgkin's Disease and T-cell lymphoma. With multiple partners, such as industry leaders Genentech, Roche, Centocor and MedImmune, Xencor is applying its suite of XmAb antibody Fc domains to improve antibody drug candidates for traits such as potency and sustained half-life. Xencor also develops therapeutic protein variants in collaboration with major pharmaceutical partners. For more information, please visit www.xencor.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.